更新乳腺癌2024第2部分-早期乳腺癌患者。

IF 2.4 4区医学 Q2 OBSTETRICS & GYNECOLOGY

Geburtshilfe Und Frauenheilkunde Pub Date : 2025-05-15 eCollection Date: 2025-05-01 DOI:10.1055/a-2533-2783

Wolfgang Janni, Hans-Christian Kolberg, Andreas D Hartkopf, Tanja N Fehm, Manfred Welslau, Volkmar Müller, Florian Schütz, Peter A Fasching, Christian Jackisch, Frederik Marme, Manuel Hörner, Katharina Keller, Chloë Goossens, Erik Belleville, Michael Untch, Marc Thill, Hans Tesch, Nina Ditsch, Michael P Lux, Maggie Banys-Paluchowski, Achim Wöckel, Nadia Harbeck, Elmar Stickeler, Rupert Bartsch, Bahriye Aktas, Andreas Schneeweiss, Johannes Ettl, Florin-Andrei Taran, Diana Lüftner, Rachel Würstlein, Julia C Radosa

{"title":"更新乳腺癌2024第2部分-早期乳腺癌患者。","authors":"Wolfgang Janni, Hans-Christian Kolberg, Andreas D Hartkopf, Tanja N Fehm, Manfred Welslau, Volkmar Müller, Florian Schütz, Peter A Fasching, Christian Jackisch, Frederik Marme, Manuel Hörner, Katharina Keller, Chloë Goossens, Erik Belleville, Michael Untch, Marc Thill, Hans Tesch, Nina Ditsch, Michael P Lux, Maggie Banys-Paluchowski, Achim Wöckel, Nadia Harbeck, Elmar Stickeler, Rupert Bartsch, Bahriye Aktas, Andreas Schneeweiss, Johannes Ettl, Florin-Andrei Taran, Diana Lüftner, Rachel Würstlein, Julia C Radosa","doi":"10.1055/a-2533-2783","DOIUrl":null,"url":null,"abstract":"This review summarizes the latest developments for the treatment of patients with early-stage breast cancer. Most of the clinically relevant changes were the result of using immune checkpoint inhibitors to treat patients with triple-negative breast cancer (TNBC) and CDK4/6 inhibitors to treat patients with hormone receptor-positive, HER2-negative (HRpos/HER2neg) tumors and a high risk of recurrence. Recent studies are presenting more and more data with long follow-up times and integrating translational analyses to evaluate new biomarkers such as circulating tumor DNA (ctDNA). This review article summarizes the latest developments published in recent months and puts the findings in context.","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"85 5","pages":"493-506"},"PeriodicalIF":2.4000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12081099/pdf/","citationCount":"0","resultStr":"{\"title\":\"Update Breast Cancer 2024 Part 2 - Patients with Early Stage Breast Cancer.\",\"authors\":\"Wolfgang Janni, Hans-Christian Kolberg, Andreas D Hartkopf, Tanja N Fehm, Manfred Welslau, Volkmar Müller, Florian Schütz, Peter A Fasching, Christian Jackisch, Frederik Marme, Manuel Hörner, Katharina Keller, Chloë Goossens, Erik Belleville, Michael Untch, Marc Thill, Hans Tesch, Nina Ditsch, Michael P Lux, Maggie Banys-Paluchowski, Achim Wöckel, Nadia Harbeck, Elmar Stickeler, Rupert Bartsch, Bahriye Aktas, Andreas Schneeweiss, Johannes Ettl, Florin-Andrei Taran, Diana Lüftner, Rachel Würstlein, Julia C Radosa\",\"doi\":\"10.1055/a-2533-2783\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This review summarizes the latest developments for the treatment of patients with early-stage breast cancer. Most of the clinically relevant changes were the result of using immune checkpoint inhibitors to treat patients with triple-negative breast cancer (TNBC) and CDK4/6 inhibitors to treat patients with hormone receptor-positive, HER2-negative (HRpos/HER2neg) tumors and a high risk of recurrence. Recent studies are presenting more and more data with long follow-up times and integrating translational analyses to evaluate new biomarkers such as circulating tumor DNA (ctDNA). This review article summarizes the latest developments published in recent months and puts the findings in context.\",\"PeriodicalId\":12481,\"journal\":{\"name\":\"Geburtshilfe Und Frauenheilkunde\",\"volume\":\"85 5\",\"pages\":\"493-506\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2025-05-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12081099/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Geburtshilfe Und Frauenheilkunde\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1055/a-2533-2783\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/5/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Geburtshilfe Und Frauenheilkunde","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-2533-2783","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

本文综述了早期乳腺癌治疗的最新进展。大多数临床相关的变化是使用免疫检查点抑制剂治疗三阴性乳腺癌（TNBC）患者和CDK4/6抑制剂治疗激素受体阳性，her2阴性（HRpos/ her2阴性）肿瘤和复发风险高的患者的结果。最近的研究提供了越来越多的数据和长时间的随访，并整合了翻译分析来评估新的生物标志物，如循环肿瘤DNA （ctDNA）。这篇综述文章总结了最近几个月发表的最新进展，并将研究结果置于背景中。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Update Breast Cancer 2024 Part 2 - Patients with Early Stage Breast Cancer.

This review summarizes the latest developments for the treatment of patients with early-stage breast cancer. Most of the clinically relevant changes were the result of using immune checkpoint inhibitors to treat patients with triple-negative breast cancer (TNBC) and CDK4/6 inhibitors to treat patients with hormone receptor-positive, HER2-negative (HRpos/HER2neg) tumors and a high risk of recurrence. Recent studies are presenting more and more data with long follow-up times and integrating translational analyses to evaluate new biomarkers such as circulating tumor DNA (ctDNA). This review article summarizes the latest developments published in recent months and puts the findings in context.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Geburtshilfe Und Frauenheilkunde 医学-妇产科学

CiteScore

2.50

自引率

22.20%

发文量

828

审稿时长

6-12 weeks

期刊介绍： Geburtshilfe und Frauenheilkunde (GebFra) addresses the whole field of obstetrics and gynecology and is concerned with research as much as with clinical practice. In its scientific section, it publishes original articles, reviews and case reports in all fields of the discipline, namely gynecological oncology, including oncology of the breast obstetrics and perinatal medicine, reproductive medicine, and urogynecology. GebFra invites the submission of original articles and review articles. In addition, the journal publishes guidelines, statements and recommendations in cooperation with the DGGG, SGGG, OEGGG and the Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF, Association of Scientific Medical Societies, www.awmf.org). Apart from the scientific section, Geburtshilfe und Frauenheilkunde has a news and views section that also includes discussions, book reviews and professional information. Letters to the editors are welcome. If a letter discusses an article that has been published in our journal, the corresponding author of the article will be informed and invited to comment on the letter. The comment will be published along with the letter.